Pharmacological evaluation of clomacran, a new potent psychotropic agent.
D000166:Acridines / Q000494:pharmacology*; D000067956:Adenylyl Cyclase Inhibitors; D000818:Animals; D014150:Antipsychotic Agents / Q000494:pharmacology*; D001058:Apomorphine / Q000037:antagonists & inhibitors; D001341:Autonomic Nervous System / Q000187:drug effects; D001480:Basal Ganglia Diseases / Q000139:chemically induced; D001522:Behavior, Animal / Q000187:drug effects; D002746:Chlorpromazine / Q000494:pharmacology; D002749:Chlorprothixene / Q000494:pharmacology; D003213:Conditioning, Psychological / Q000187:drug effects; D003342:Corpus Striatum / Q000187:drug effects / Q000378:metabolism; D004285:Dogs; D004298:Dopamine / Q000378:metabolism; D005260:Female; D000882:Haplorhini; D006439:Hemodynamics / Q000187:drug effects; D006801:Humans; D007928:Lethal Dose 50; D008253:Macaca mulatta; D008297:Male; D051379:Mice; D009043:Motor Activity / Q000187:drug effects; D011889:Rage / Q000187:drug effects; D051381:Rats; D011930:Reaction Time / Q000187:drug effects; D013239:Stereotyped Behavior / Q000187:drug effects; D014268:Trifluoperazine / Q000494:pharmacology
D000166:Acridines; D000067956:Adenylyl Cyclase Inhibitors; D014150:Antipsychotic Agents; D014268:Trifluoperazine; D002749:Chlorprothixene; D001058:Apomorphine; D002746:Chlorpromazine; D004298:Dopamine